Introduction
Chediak-Higashi syndrome (CHS) is a rare autosomalrecessive disorder, characterized by oculocutaneous albinism, recurrent infections, microscopic finding of large granules in hematopoietic and other cells, bleeding diathesis and neurologic abnormalities. [1] [2] [3] Pathologic mutations in the lysosomal trafficking regulator gene localized to human chromosome 1q42-q43 are responsible for development of CHS. 4, 5 Neutropenia and defects in natural killer cell activity, T-cell cytotoxicity, chemotaxis and bactericidal killing by granulocytes and monocytes result in increased susceptibility to infection. 6, 7 In survivors of infectious complications, an accelerated phase, manifested by life-threatening hemophagocytosis, typically associated with Epstein Barr virus infection, occurs within the first or second decade. The accelerated phase of CHS is characterized by lymphocyte and macrophage activation with diffuse lymphohistiocytic infiltration of liver, spleen, lymph nodes, central nervous system and bone marrow. This is the most frequent cause of mortality in patients with CHS. 4, 8 Transient remissions are reported after treatment with etoposide, corticosteroids and supportive care; relapses are frequent and are increasingly resistant to treatment. [9] [10] [11] Published reports suggest that allogeneic hematopoietic cell transplantation (HCT) may be effective therapy for the accelerated phase of CHS; however, these studies are limited by small numbers of patients. Additionally, most reports describe outcomes only after human leukocyte antigen (HLA)-matched sibling transplants. [11] [12] [13] [14] [15] The purpose of this study was to determine whether similar outcomes could be expected after HLA-matched sibling, alternative related and unrelated donor transplants. In this retrospective descriptive analysis, we report outcomes after HCT for CHS in 35 patients transplanted between 1 January 1980 and 31 December 1999 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
Patients and methods

Data collection
The CIBMTR is a working group of over 500 transplant centers worldwide that voluntarily contribute data on their allogeneic transplants to a Statistical Center at the Medical College of Wisconsin. Participating centers register and provide basic information on all consecutive transplantations. Detailed demographic, disease and transplant characteristics and outcome data are collected on a sample of registered patients including virtually all adult unrelated donor transplants in the US. Patients are followed longitudinally. Computerized error checks, physician review of submitted data, and on-site audits of participating centers ensure data quality.
Inclusion criteria
Patients with CHS transplanted in 1989-1999 and reported to the CIBMTR (n ¼ 40) were eligible for this study.
Comprehensive pre-and post-transplant clinical information were available for 35 (88%) patients. The diagnosis of CHS was based on the constellation of clinical findings of oculocutaneous albinism, giant leukocyte granules, neutropenia, recurrent infections and neurological dysfunction with or without abnormal natural killer cell function. The cases in this review were ascertained before publication of the genetic defect responsible for CHS.
End points
Hematopoietic recovery was defined as achieving an absolute neutrophil count (ANC) of X0.5 Â 10 9 /l for three consecutive days and platelets X20 Â 10 9 /l. Diagnosis of acute and chronic graft-versus-host disease (GVHD) was based on local institutional criteria with overall grade assigned retrospectively by the CIBMTR based on stage of involvement reported for each individual organ. 16, 17 Death from any cause was considered an event. Surviving patients were censored at last follow-up.
Statistical analysis
The probability of overall survival was calculated using the Kaplan-Meier estimator and the confidence interval, calculated with the use of a log transformation. 18 This was performed using the statistical package SAS version 9.1 (Carey, NC, USA).
Results
Patient and transplant characteristics
Patient and transplant characteristics are shown in Table 1 . Median age at transplantation was 5 (range, 1-19) years. Before HCT, patients received variable treatments with corticosteroids, acyclovir, g-globulin, etoposide, anti-thymocyte globulin and intrathecal methotrexate for management of clinical features of the disease. Twenty-two patients had a history life-threatening accelerated phase of CHS before transplantation and of these, 11 were in accelerated phase at transplantation. Ten patients were transplanted before development of symptoms or signs of accelerated phase and these data were not available for three patients. Thirteen patients received allografts from an HLA-identical sibling. Among recipients of alternative related donor transplants, three received allografts from an HLAidentical parent, three from a one-antigen mismatched parent or sibling, and the remaining four, from haploidentical parents. Five received allografts from an HLAidentical unrelated donor and the remaining seven, from one-antigen mismatched donors (HLA A and B at the antigen level by intermediate resolution and allele-level DRB1). All received bone marrow grafts except 1 who received peripheral blood. Six bone marrow grafts were Tcell-depleted and included grafts from haplo-identical parent (n ¼ 4), one-antigen mismatched sibling (n ¼ 1) and matched unrelated donor (n ¼ 1). The most common preparative regimen utilized the combination of oral busulfan and intravenous cyclophosphamide. The median follow-up of the study population is 80 months (range 14-174). 
Hematopoietic recovery
The median time to neutrophil and platelet recovery was 18 (range, 7-35) days and 32 (15-152) days, respectively. Two patients failed to achieve hematopoietic recovery; both received bone marrow grafts from alternative related donors. One patient died before second transplantation and the other underwent a second transplant, achieved hematopoietic recovery but died from persistent disease (day 47 after second transplant). Both patients were in accelerated phase at transplantation. 
Graft-versus-host disease
Overall survival
The 5-year probability of overall survival is 62% (95% CI 44-76). Table 2 shows survival and disease status of patients after transplantation by disease status pre-transplant and donor type. Twenty-two patients are alive and 21 are in hematologic remission with performance scores 490%. One patient is alive, 10 years after HCT with recurrent disease (presence of leukocyte granules 7.4 months after transplantation) but without symptoms of accelerated phase. One of the patients in remission from CHS developed myelodysplastic syndrome. She received a second allogeneic transplant 4 years after the first transplant and remains free of both diseases, 9 years from the first transplant and 5 years from the second. Data on donor-recipient chimerism were available for 13 of 22 surviving patients. Of these, 10 patients are reported to have 100% donor chimerism. The remaining three patients have 92, 70 and 15% donor chimerism. Only the Causes of death Overall, 13 patients died after HCT from either persistent disease or a transplant-related complication. Nine patients died within 100 days of transplantation (early mortality). Of these, six received allografts from an alternative related donor, one from an HLA-matched sibling, and the remaining two, from an unrelated donor. Causes of early mortality included: persistent disease (n ¼ 6) in recipients of alternative related donor HCT, adenoviral infection (n ¼ 1) and adult respiratory distress syndrome (n ¼ 1) in recipients of unrelated donor HCT, and veno-occlusive disease (n ¼ 1) after an HLA-matched sibling donor HCT. Causes of late mortality (4100 days) included persistent disease (n ¼ 1) after an alternative related donor HCT, systemic fungal infection (n ¼ 1) and idiopathic interstitial pneumonitis (n ¼ 1) after unrelated donor HSCT and chronic GVHD (n ¼ 1) after an HLA-matched sibling donor HCT.
Discussion
We describe outcomes after allogeneic transplantation for 35 patients with CHS. In general, these data suggest allogeneic transplantation from an HLA-matched sibling or an unrelated donor may be an effective treatment for hematologic and immunologic correction of CHS, and a history of symptoms of accelerated phase does not preclude a successful outcome. Survival after alternative related donor HCT was poor. This may be explained by the presence of symptoms of accelerated phase at transplantation in most of these recipients. The absence of symptoms of accelerated phase at transplant appears to predict fewer recurrences. A recent retrospective review of transplantation for CHS indicates a high rate of neurocognitive sequelae in patients who have survived into their third decade after HCT. 19 A number of the patients in that series had mixed chimerism post HCT. It is not known to what extent the experience of the accelerated phase before HCT contributes to later neurocognitive deficits, and, conversely, whether HCT at a younger age could reduce or delay later neurologic deterioration. The occurrence of mild central or peripheral neuropathy in this series cannot be excluded, despite reports of excellent performance scores in the survivors and is a limitation of any registry-based study. Further, ours is a relatively young cohort, the median age of surviving patients is 12 years and the two oldest patients are 21 years of age.
Although data on donor-recipient chimerism were available for only 76% of surviving patients the data suggest that in the majority of patients long-term engraftment is durable. In those with mixed donor-recipient chimerism, only one patient has clinical evidence of recurrent disease as evidenced by the presence of leukocyte granules (15% donor chimerism). Importantly, this patient has maintained a low level of donor chimerism for almost 10 years and without symptoms of the accelerated phase of this disease.
Early mortality after transplantation was high with most deaths (nine of 13) occurring within 100 days after transplantation. Persistent disease was the most common cause of early mortality and occurred in patients transplanted in accelerated phase. Although GVHD was more frequent after unrelated donor transplantation this did not affect mortality. Although the study period spans over two decades, we did not observe differences in overall survival by year of transplantation. Our inability to detect differences in survival outcomes may be explained by the small cohort and over half of the deaths were due to recurrent disease occurring in patients with active disease at transplantation.
The current report has several limitations: small sample size, lack of detailed information on immune reconstitution and post-transplant extrahematopoietic manifestations such as neurological outcomes. Nevertheless, the data suggest HLA-matched and unrelated donor HCT with a myeloablative preparatory regimen offer a cure for an otherwise lethal disease. The poor outcome associated with accelerated phase disease at transplantation warrant confirmation in a larger study. Future studies of HCT treatment for CHS, as with other hemophagocytic disorders, should build in longitudinal neurocognitive monitoring as well as examine the role of alternative related donor HCT in patients without active disease at transplantation.
